Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 4;13(3):291-296.
doi: 10.1093/ckj/sfaa082. eCollection 2020 Jun.

A brand-new cardiorenal syndrome in the COVID-19 setting

Mugurel Apetrii  1   2 , Stefana Enache  3 , Dimitrie Siriopol  1   2 , Alexandru Burlacu  2   4 , Asiye Kanbay  5 , Mehmet Kanbay  6 , Dragos Scripcariu  2   7 , Adrian Covic  1   2
Affiliations
Review

A brand-new cardiorenal syndrome in the COVID-19 setting

Mugurel Apetrii et al. Clin Kidney J. .

Abstract

Coronaviruses are a major pathogen for adults, causing up to one-third of community-acquired respiratory tract infections in adults during epidemics. Although the pandemic outbreak of coronavirus disease-2019 (COVID-19) targets preferentially patient's lungs, recent data have documented that COVID-19 causes myocarditis, acute myocardial infarction, exacerbation of heart failure and acute kidney injury. Studies show that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), similar to its predecessor SARS-CoV, engages angiotensin-converting enzyme 2 (ACE2) as the entry receptor. ACE2 is also expressed in the heart, providing a link between coronaviruses and the cardiovascular system.

Keywords: ACE2; CKD; COVID-19; cardiorenal syndrome; myocardial injury.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
The main physiopathological pathways of cardiorenal syndrome associated with SARS-CoV-2 infection.
See this image and copyright information in PMC

References

    1. Rangaswami J, Bhalla V, Blair JEA. et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019; 139: e840–e878 - PubMed
    1. Ronco C, Haapio M, House AA. et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527–1539 - PubMed
    1. Sun ML, Yang JM, Sun YP. et al. [ Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 219–222. - PubMed
    1. Driggin E, Madhavan MV, Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; doi: 10.1016/j.jacc.2020.03.031 - PMC - PubMed
    1. Tam CF, Cheung KS, Lam S. et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes2020: doi: 10.1161/circoutcomes.120.006631 - PMC - PubMed